The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial-Reference-Cited by-同舟云学术

The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial

Published:2016-01-05 Issue:1 Volume:173 Page:96-104
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Armand Philippe¹,Kim Haesook T.²,Sainvil Marie-Michele¹,Lange Paulina B.¹,Giardino Angela A.³,Bachanova Veronika⁴,Devine Steven M.⁵,Waller Edmund K.⁶,Jagirdar Neera⁶,Herrera Alex F.⁷,Cutler Corey¹,Ho Vincent T.¹,Koreth John¹,Alyea Edwin P.¹,McAfee Steven L.⁸,Soiffer Robert J.¹,Chen Yi-Bin⁸,Antin Joseph H.¹

Affiliation:

1. Department of Medical Oncology; Dana-Farber Cancer Institute; Boston MA USA

2. Biostatistics and Computational Biology; Dana-Farber Cancer Institute; Boston MA USA

3. Department of Radiology; Brigham and Women's Hospital; Boston MA USA

4. Department of Medical Oncology; University of Minnesota; Minneapolis MN USA

5. Department of Medicine; The Ohio State University Comprehensive Cancer Center Ohio State University; Columbus OH USA

6. Department of Hematology/Oncology; Winship Cancer Institute; Emory University; Atlanta GA USA

7. City of Hope Cancer Center; Duarte CA USA

8. Bone Marrow Transplant Unit; Division of Hematology/Oncology; Massachusetts General Hospital; Boston MA USA

Funder

National Institute of Allergy and Infectious Diseases

National Cancer Institute

Jock and Bunny Adams Research and Education Endowment

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13931/fullpdf

Reference35 articles.

1. Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation;Alyea;Biology of Blood and Marrow Transplantation,2008

2. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group;Ansell;Cancer,2008

3. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study;Ansell;Lancet Oncol,2011

4. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation;Antin;Blood,2003

5. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning;Armand;Journal of Clinical Oncology,2008

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Approaches for the Prevention and Treatment of Acute and Chronic GVHD;Cells;2024-09-11

2. Acute Graft‐versus‐Host Disease;Cancer Consult;2023-11-18

3. Novel developments in the prophylaxis and treatment of acute GVHD;Blood;2023-09-21

4. Pharmacologic Differentiation of Drugs Targeting the PI 3K‐ AKT ‐m TOR Signaling Pathway;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

5. Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway;Current Oncology Reports;2022-06-13